Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2
and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates …

An efficacious COVID-19 vaccine is currently the world's leading research priority. Several
nations have indicated that if there is a compelling case for use of a vaccine before it is …

Background: Recently emerging results from a few placebo-controlled randomized trials of
COVID-19 vaccines revealed estimates of 62%–95% relative reductions in risk of …

Abstract Coronavirus disease 2019 (COVID-19) vaccine trials provide valuable insight into
the safety and efficacy of vaccines, with individually randomized, placebo-controlled trials …

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …

Public health professionals and clinicians, in many countries, are immersed in the ongoing
and upcoming vaccination programmes for COVID-19. Published information from vaccine …

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …

After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several
manufacturers for protection against severe disease, a comprehensive post-efficacy strategy …

Three issues are crucial in planning COVID19 vaccine trials:(1) whether to demand not only
proof of some vaccine efficacy but also proof of worthwhile efficacy;(2) whether the initial …

On Aug 17, 2020, screening began for participants to enrol in the midstage study of an
experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation …